MCID: IND003
MIFTS: 23

Indolent Myeloma

Categories: Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Indolent Myeloma

MalaCards integrated aliases for Indolent Myeloma:

Name: Indolent Myeloma 12 14 69
Indolent Multiple Myeloma 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9550
UMLS 69 C1334169

Summaries for Indolent Myeloma

MalaCards based summary : Indolent Myeloma, also known as indolent multiple myeloma, is related to theileriasis and lung lymphoma, and has symptoms including bone pain An important gene associated with Indolent Myeloma is MYOM2 (Myomesin 2). The drugs rituximab and Alkylating Agents have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow.

Related Diseases for Indolent Myeloma

Diseases related to Indolent Myeloma via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 theileriasis 9.9 B2M MYOM2
2 lung lymphoma 9.9 B2M MYOM2
3 adrenal gland disease 9.8 B2M MYOM2
4 hypogonadotropism 9.8 B2M MYOM2
5 angiomatous meningioma 9.7 B2M MYOM2
6 malignant melanocytic peripheral nerve sheath tumor of mediastinum 9.6 B2M MYOM2
7 cpt deficiency, hepatic, type ia 9.4 B2M MYOM2
8 smoking as a quantitative trait locus 1 9.4 ANXA5 B2M
9 peripheral nerve schwannoma 8.6 ANXA5 B2M MYOM2 OSM

Graphical network of the top 20 diseases related to Indolent Myeloma:



Diseases related to Indolent Myeloma

Symptoms & Phenotypes for Indolent Myeloma

UMLS symptoms related to Indolent Myeloma:


bone pain

Drugs & Therapeutics for Indolent Myeloma

Drugs for Indolent Myeloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
2 Alkylating Agents Phase 3,Phase 2,Phase 1
3 Antirheumatic Agents Phase 3,Phase 2,Phase 1
4 Bendamustine Hydrochloride Phase 3
5
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
6
Bisacodyl Approved Phase 2 603-50-9
7
Bismuth Subsalicylate Approved, Vet_approved Phase 2 14882-18-9 53629521
8
Lactulose Approved Phase 2 4618-18-2 11333
9
Magnesium Hydroxide Approved Phase 2 1309-42-8
10
Magnesium oxide Approved Phase 2 1309-48-4 14792
11
Pamidronate Approved Phase 2 40391-99-9 4674
12
Zoledronic acid Approved Phase 2 118072-93-8 68740
13
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
14
Obinutuzumab Approved Phase 1, Phase 2 949142-50-1
15
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
16 Pomalidomide Approved Phase 2 19171-19-8
17 Vaccines Phase 1, Phase 2
18 Antiemetics Phase 2,Phase 1
19 Anti-Inflammatory Agents Phase 2,Phase 1
20 Antineoplastic Agents, Hormonal Phase 2,Phase 1
21 Autonomic Agents Phase 2,Phase 1
22 BB 1101 Phase 2,Phase 1
23 Dexamethasone acetate Phase 2,Phase 1 1177-87-3
24 Gastrointestinal Agents Phase 2,Phase 1
25 glucocorticoids Phase 2,Phase 1
26 HIV Protease Inhibitors Phase 2,Phase 1
27 Hormone Antagonists Phase 2,Phase 1
28 Hormones Phase 2,Phase 1
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Phase 1
30 Interleukin 1 Receptor Antagonist Protein Phase 2,Phase 1
31 Peripheral Nervous System Agents Phase 2,Phase 1
32
protease inhibitors Phase 2,Phase 1
33 Angiogenesis Inhibitors Phase 2,Phase 1
34 Angiogenesis Modulating Agents Phase 2,Phase 1
35 Anti-Bacterial Agents Phase 2,Phase 1
36 Anti-Infective Agents Phase 2,Phase 1
37 Bone Density Conservation Agents Phase 2
38 Diphosphonates Phase 2
39 Immunosuppressive Agents Phase 2,Phase 1
40 Radiopharmaceuticals Phase 2
41 Omega 3 Fatty Acid Nutraceutical Phase 2
42 Siltuximab Approved Phase 1 541502-14-1
43
Everolimus Approved Phase 1 159351-69-6 6442177
44
Fludarabine Approved Phase 1 21679-14-1, 75607-67-9 30751
45
Mesna Approved Phase 1 3375-50-6 598
46
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189
47
Sirolimus Approved, Investigational Phase 1 53123-88-9 5284616 6436030 46835353
48
Vidarabine Approved Phase 1 24356-66-9 32326 21704
49 Antibodies Phase 1
50 Antibodies, Monoclonal Phase 1

Interventional clinical trials:

(show all 14)

id Name Status NCT ID Phase Drugs
1 Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia Completed NCT01500083 Phase 3 Bendamustine at a dose of 100 mg/m2;Bendamustine at a dose of 120 mg/m2
2 Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma Unknown status NCT00937183 Phase 1, Phase 2
3 Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma Completed NCT00635154 Phase 2 Dexamethasone acetate
4 Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide Completed NCT00083382 Phase 2 Pamidronate;Thalidomide;Zometa
5 Lenalidomide and GA101 in Relapsed Indolent Non-Hodgkin's Lymphoma Recruiting NCT01995669 Phase 1, Phase 2 Lenalidomide;Obinutuzumab (GA101)
6 Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies Recruiting NCT02952508 Phase 2 CLR 131
7 Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma Active, not recruiting NCT02492750 Phase 1, Phase 2 Dexamethasone;Lenalidomide
8 Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide Active, not recruiting NCT02046915 Phase 2 Imnovid (pomalidomide);Dexamethasone;Endoxan (Cyclophosphamide)
9 Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma Active, not recruiting NCT01316523 Phase 2 Rituximab;Lenalidomide
10 Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) Terminated NCT00899353 Phase 2
11 A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma Completed NCT01219010 Phase 1
12 Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies Terminated NCT00473551 Phase 1 Rituximab;Cyclophosphamide;Fludarabine;Mesna;Sirolimus
13 Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI : Added Value of Diffusion Weighted Imaging Unknown status NCT01780766
14 Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM. Active, not recruiting NCT01079429

Search NIH Clinical Center for Indolent Myeloma

Genetic Tests for Indolent Myeloma

Anatomical Context for Indolent Myeloma

MalaCards organs/tissues related to Indolent Myeloma:

39
B Cells, Bone, Bone Marrow, Heart

Publications for Indolent Myeloma

Articles related to Indolent Myeloma:

id Title Authors Year
1
Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. ( 20730790 )
2010
2
Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease. ( 19181642 )
2009
3
A smoldering/indolent myeloma with extensive abdominal presentation--case report. ( 16986300 )
2006
4
Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. ( 12100153 )
2002
5
Smoldering, asymptomatic stage 1, and indolent myeloma. ( 12057049 )
2000
6
Coexistence of Polycythaemia Vera with Indolent Myeloma in the same Patient. ( 27406804 )
1997
7
Localized and indolent myeloma. ( 7407416 )
1980

Variations for Indolent Myeloma

Expression for Indolent Myeloma

Search GEO for disease gene expression data for Indolent Myeloma.

Pathways for Indolent Myeloma

GO Terms for Indolent Myeloma

Cellular components related to Indolent Myeloma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.62 ANXA5 B2M

Sources for Indolent Myeloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....